Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Abstract

Neoadjuvant nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors. The tumor mutational burden was predictive of the pathological response to PD-1 blockade. Treatment induced expansion of mutation-associated, neoantigen-specific T-cell clones in peripheral blood. (Funded by Cancer Research Institute-Stand Up 2 Cancer and others; ClinicalTrials.gov number, NCT02259621 .).

Keywords

Affiliated Institutions

• Sidney Kimmel Comprehensive Cancer Center US
• Johns Hopkins University US
• Cornell University US
• Memorial Sloan Kettering Cancer Center US
• Weill Cornell Medicine US
• Swim Across America US
• Parker Institute for Cancer Immunotherapy US
• Bloomberg (United States) US

Related Publications